Carcinoma of the Cervix Uteri

Quinn, Michael; Benedet, J.L.; Odicino, Franco; Maisonneuve, Patrick; Beller, U.; Creasman, William T.; Heintz, A.P.M.; Ngan, Hextan Y.S.; Pecorelli, Sërgio

doi:10.1016/s0020-7292(06)60030-1

Cited by 514 publications

(189 citation statements)

References 0 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Written consent from each patient and approval from the Institutional Research Ethics Committee were obtained. Tumors were diagnosed by 2 expert pathologists according to the grading system defined by the 2009 International Federation of Gynecology and Obstetrics (FIGO) for tumors of the cervical cancer (Quinn et al, 2006;Pecorelli, 2009). All samples were acquired at the time of surgery from unfixed tissue, and the samples were immediately frozen and stored at -196°C in liquid nitrogen until further analysis.…”

Section: Patients and Clinical Samplesmentioning

confidence: 99%

FOXO1 is a tumor suppressor in cervical cancer

Zhang¹,

Gui²,

Zhao³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Forkhead box protein O1 (FOXO1) is an important transcriptional regulator of cell proliferation, and is considered essential for tumor growth and progression. However, the function of FOXO1 in human cervical cancer remains unclear. In this study, we investigated the role of FOXO1 in cervical cancer. Our results showed that FOXO1 expression was lower in cervical cancer than in cervical intraepithelial neoplasia and normal cervix by immunohistochemical analysis (P < 0.05). The level of FOXO1 in high-grade lesions was significantly lower than in low-grade lesion (P < 0.05), indicating that deficient expression of FOXO1 is involved in tumor progression and significantly associated with late-stage tumors (P < 0.05), which was further supported by clinicopathological, real-time polymerase chain reaction, and Western blotting analysis. Moreover, we confirmed that the overexpression of FOXO1 remarkably repressed cell growth and blocked cell proliferation, accompanied by cell-cycle arrest in the G 2 /M phase and upregulation of caspases-3 and -9 gene expression. Collectively, our data suggest that FOXO1 plays a vital role in inhibiting cervical cancer development by inducing cell-cycle arrest 6605-6616 (2015) and apoptosis. FOXO1 expression is a favorable prognostic factor for human cervical cancer.

show abstract

Section: Patients and Clinical Samplesmentioning

confidence: 99%

FOXO1 is a tumor suppressor in cervical cancer

Zhang¹,

Gui²,

Zhao³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Patients newly diagnosed with CC between 2004 and 2008 were identified using the following inclusion criteria: (a) an initial diagnosis of CC as a primary tumor, (b) the presence ofstage I-IIA disease according to the American Joint Cancer Committee on Cancer system (sixth edition) [19] and International Federation of Gynecology and Obstetrics staging system (1994) [20], and (c) age $40 years. Patients with the following characteristics were excluded: (a) had other cancers in the past; (b) exhibited multiple primary cancers; (c) exhibited pathology other than squamous cell carcinoma or adenocarcinoma; (d) received treatment other than standard curative treatment (surgery, definitive radiotherapy, and concurrent chemoradiation), such as neoadjuvant chemotherapy, chemotherapy alone, or unknown therapy (missing data); and (e) exhibited a positive or unknown surgical margin.…”

Section: Study Populationmentioning

confidence: 99%

The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia

et al. 2015

View full text Add to dashboard Cite

Background. Many studies have shown that type 2 diabetes mellitus (DM) increases the risk for several types of cancer but not cervical cancer (CC). Although DM and insulin‐like growth factor 1 have preclinical and clinical implications for CC, less is known about the prognostic impact of DM on patients with early stage CC. Patients and Methods. We used the nationwide Taiwan Cancer Registry database to collect the characteristics of stage I–IIA cervical cancer patients diagnosed between 2004 and 2008. DM and other comorbidities were retrieved from the National Health Insurance database. Cervical cancer‐specific survival (CSS) and overall survival (OS) times of patients according to DM status were estimated using the Kaplan‐Meier method. We used a Cox proportional hazards model to calculate adjusted hazard ratios (HRs) for the effects of DM and other risk factors on mortality. Results. A total of 2,946 patients had primary stage I–IIA CC and received curative treatments, and 284 (9.6%) had DM. The 5‐year CSS and OS rates for patients with DM were significantly lower than those without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%). After adjusting for clinicopathologic variables and comorbidities, DM remained an independent unfavorable prognostic factor for CSS (adjusted HR: 1.46) and OS (adjusted HR: 1.55). Conclusion. In Asian patients with early cervical cancer, DM is an independent unfavorable prognostic factor influencing both OS and CSS, even after curative treatments. Implications for Practice: Type 2 diabetes mellitus (DM) increases the incidence of several types of cancer but not cervical cancer (CC); however, less is known about the impact of DM on patients who already have CC. This study suggests that DM may increase the risk of cancer recurrence and death for early stage CC patients, even after curative treatments. Incorporating DM control should be considered part of the continuum of care for early stage CC patients, and close surveillance during routine follow‐up in this population is recommended.

show abstract

“…Stage I tumor is basically limited to the cervix, as opposed to stage II to IV which extend beyond the cervix. In the whole world, the 2006 FIGO report indicated that 42% of cervical cancer cases are diagnosed at stage I, 30% at stage II, 21% at stage III and 6% at stage IV (Quinn et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

“…In terms of sexual functioning, a few studies showed that sexual functioning had significant association with stage of cancer among the cervical cancer survivors (Quinn et al, 2006;Hsu et al, 2009;Mantegna et al, 2013). Another study also found that tumor stage directly affected sexual function in women with gynecologic cancer (Chun, 2008).…”

Section: Introductionmentioning

confidence: 99%